risonate
teva pharma b.v. - natrio rizedronatas - plėvele dengtos tabletės - 35 mg - risedronic acid
velbienne
exeltis baltics, uab - estradiolio valeratas/dienogestas - plėvele dengtos tabletės - 1 mg/2 mg - dienogest and estrogen
allopurinol accord
accord healthcare b.v. - alopurinolis - tabletės - 100 mg - allopurinol
allopurinol accord
accord healthcare b.v. - alopurinolis - tabletės - 300 mg - allopurinol
riximyo
sandoz gmbh - rituksimabas - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antinavikiniai vaistai - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. tik ribotą duomenų apie veiksmingumą ir saugumą pacientams, anksčiau gydomi monokloniniai antikūnai, įskaitant rituximab ar pacientams, ugniai atsparios į ankstesnį rituximab plius chemoterapija. Žr. skyrių 5. 1, jei norite gauti daugiau informacijos. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab buvo įrodyta, kad sumažinti greitį progresavimą, bendrą žalą, vertinant pagal x-ray ir gerinti fizinę funkciją, skiriant kartu su metotreksatu. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).
axympa
teva b.v. - mikofenolio rūgštis - skrandyje neirios tabletės - 180 mg; 360 mg - mycophenolic acid
cinacalcet teva
teva b.v. - cinakalcetas - plėvele dengtos tabletės - 90 mg; 30 mg; 60 mg - cinacalcet
octaplasma
octapharma (ip) sprl - Žmogaus plazmos baltymai - infuzinis tirpalas - 40-70 mg/ml - blood substitutes and plasma protein fractions
quinapril/hct teva
teva pharma b.v. - kvinaprilis/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/12,5 mg; 20 mg/12,5 mg - quinapril and diuretics
rosuvastatin accord
accord healthcare b.v. - rozuvastatinas - plėvele dengtos tabletės - 40 mg; 10 mg; 5 mg; 20 mg - rosuvastatin